# First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations

> **NCT07699952** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yongsheng Wang** · enrollment: 35 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)
- EGFR Activating Mutation
- HER2

## Interventions

- **DRUG:** Almonertinib
- **DRUG:** Trastuzumab Rezetecan

## Key facts

- **NCT ID:** NCT07699952
- **Lead sponsor:** Yongsheng Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-09
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07699952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07699952, "First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07699952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*